Skip to main content

Table 2 Biopsy next-generation genomic sequencing results

From: Multiparametric bone MRI targeting aides lesion selection for CT-guided sclerotic bone biopsies in metastatic castrate resistant prostate cancer

StudyID

Somatic Mutations

Copy Number Variations

 

Gene

Mutation

Functional Impact

 

2

SRC

TP53

p.P171L

p.R158H

Uncertain

Uncertain

AR amplification

5

EGFR

NOTCH2

TP53

p.A289V

p.C342R

p.M237I

Uncertain

Likely pathogenic

Pathogenic

MAP2K1, PTEN deep deletion AR, FANCB amplification

6

CDK12

p.G162W

Uncertain

MAP2K1, PTEN deep deletion

AR, FANCB amplification

9

TP53

c.258 + 1G > A

Pathogenic

-

10

FANCG

WT1

C308-1G

p.H359D

Pathogenic

Uncertain

-

12

-

  

PIK3R1, PTEN deep deletion

14

-

  

MAP2K4, NOTCH1, PTEN deep deletion

AR amplification

15

PIK3CA

FANCA

p.E545K

p.S132R

Pathogenic

Uncertain

-

16

PDGFRA

TP53

p.I317T

p.R273C

Uncertain

Pathogenic

-

17

XPC

c.104-2 A > G

Pathogenic

-

19

AR

ATM

BLM

FANCC

FANCF

MAP3K1

MSH6

RECQL4

p.T878A

p.T1743I

p.F663I

p.R555Q

p.A186V

p.D1170del

p.R1334W

p.G120R

Pathogenic

Likely pathogenic

Uncertain

Likely benign

Benign

Uncertain

Pathogenic

Likely benign

AR, ATRX, RECQL4 amplification

20

BRCA2

PIK3CA

TP53

p.I1859Kfs*3

p.E545K

p.R282W

Pathogenic

Pathogenic

Pathogenic

AR amplification

  1. Functional impact of each somatic mutation is rated as per ClinVar and American College of Medical Genetics and Genomics reporting recommendations, AR – androgen receptor, PTEN – phosphatase and tensin homologue